Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Dallas Hospital Seeks Dismissal of Nurse’s Suit Over Ebola

By Drug Discovery Trends Editor | April 6, 2015

A hospital operator denied allegations of poor training and improper preparation in seeking dismissal of a lawsuit by a nurse who contracted Ebola while caring for the first U.S. patient to succumb to the deadly disease.
 
Texas Health Resources filed a response Friday to the March 2 lawsuit by nurse Nina Pham, The Dallas Morning News reported Saturday.
 
Pham, who remains employed at Texas Health Presbyterian Hospital Dallas but has not returned to work, seeks unspecified damages in her lawsuit.
 
A man visiting Dallas from Liberia, Thomas Eric Duncan, died Oct. 8 at the hospital. Pham and another nurse caring for Duncan contracted Ebola but survived.
 
Texas Health Resources spokesman Wendell Watson, in a statement Friday, said the company and the hospital acted responsibly to protect their employees, basing their responses on the most up-to-date federal guidelines and with leading experts at Emory University Hospital in Atlanta.
 
The hospital also respected Pham’s privacy and acted only with her consent, the statement said. A doctor on Oct. 16 videotaped Pham, who was in a hospital bed, in images later made public.
 
“Nina Pham has gone through the unprecedented challenge of being the first nurse to whom the Ebola virus was transmitted while caring for a patient with Ebola in the U.S.,” the statement said. “Our care and compassion for Nina is paramount, and we will continue to show her the utmost courtesy, dignity and respect as a member of the Texas Health family.”
 
Since Pham contracted the disease while working for the hospital as an intensive care nurse, her remedy should be a worker’s compensation claim, not in civil court, the hospital’s response said.
 
“I am disappointed but not surprised about the answer THR filed,” said Pham’s attorney, Charla Aldous. “My hope was that they would come clean and be honest about what happened so that the health care community can learn from the mistakes made.”


Filed Under: Drug Discovery

 

Related Articles Read More >

Pharma 2035 Playbook: Speed, focus and conviction in an uncertain world
TransCelerate CEO Janice Chang wants trials to become part of routine care
STEERLife’s FragMelt platform manufactures drugs with heat sensitive active ingredient 
S&P report highlights Big Pharma’s concentration risk amid pre-JPM deal flurry
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2026 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE